Racial Disparities in the Diagnosis and Treatment of Type 1 Diabetes in Black American Youth by Mitchell, Kierra
Claremont Colleges
Scholarship @ Claremont
Scripps Senior Theses Scripps Student Scholarship
2019
Racial Disparities in the Diagnosis and Treatment
of Type 1 Diabetes in Black American Youth
Kierra Mitchell
Scripps College
This Open Access Senior Thesis is brought to you for free and open access by the Scripps Student Scholarship at Scholarship @ Claremont. It has been
accepted for inclusion in Scripps Senior Theses by an authorized administrator of Scholarship @ Claremont. For more information, please contact
scholarship@cuc.claremont.edu.
Recommended Citation
Mitchell, Kierra, "Racial Disparities in the Diagnosis and Treatment of Type 1 Diabetes in Black American Youth" (2019). Scripps
Senior Theses. 1239.
https://scholarship.claremont.edu/scripps_theses/1239
  
 
 
RACIAL DISPARITIES IN THE DIAGNOSIS AND TREATMENT  
OF TYPE 1 DIABETES IN BLACK AMERICAN YOUTH 
 
 
 
A THESIS PRESENTED  
 
BY 
 
 
 
KIERRA R. MITCHELL 
 
 
 
 
TO THE KECK SCIENCE DEPARTMENT  
OF CLAREMONT MCKENNA,  PITZER, AND SCRIPPS COLLEGES  
IN PARTIAL FULFILLMENT OF 
 THE DEGREE OF BACHELOR OF ARTS 
 
 
 
 
SENIOR THESIS IN HUMAN BIOLOGY 
 
DECEMBER 10, 2018 
 
 
 
 
 
 
 
 
 
 
RACIAL DISPARITIES IN THE DIAGNOSIS AND TREATMENT OF TYPE 1 DIABETES IN BLACK AMERICAN YOUTH 
 
 
 
Table of Contents 
Acknowledgements 2 
Introduction 4 
Background Information 6 
Genetic Factors 6 
Prevention 7 
Treatment Options 8 
Cost 9 
Literature Review 11 
Proposed contributors to the disparities faced by Black youth 11 
I. Treatment method 11 
II. Insurance coverage and socioeconomic status 12 
III. Education 15 
IV. Implicit bias among medical professionals 16 
Conclusion, Discussion & Future Research 18 
Glossary 20 
References 21 
 
 
 
 
 
 
  
1 
 
 
RACIAL DISPARITIES IN THE DIAGNOSIS AND TREATMENT OF TYPE 1 DIABETES IN BLACK AMERICAN YOUTH 
 
 
 
Acknowledgements 
I would like to sincerely thank Professor Steffanie Guillermo and Professor Jenna 
Monroy for taking the time to be my thesis readers. I am extremely grateful for their support 
and guidance throughout this process. I would also like to extend my gratitude to the W.M. 
Keck Science Department for providing me with the resources to succeed in this department.  
 
 
 
 
 
 
 
 
 
 
  
2 
 
 
RACIAL DISPARITIES IN THE DIAGNOSIS AND TREATMENT OF TYPE 1 DIABETES IN BLACK AMERICAN YOUTH 
 
 
 
Abstract 
Introduction: ​Rates of childhood-onset type 1 diabetes (T1D) are steadily increasing 
among American youth, yet Black Americans are more likely to suffer from serious 
T1D-related complications caused by poor glycemic control.​ ​The aim of this thesis is to 
determine the external factors that are causing discrepancies in the development, diagnosis, 
treatment, and long-term management of T1D in Black youth.  
Methods:​ Epidemiological studies were compiled from the ​American Diabetes 
Association, Center for Disease Control (CDC), International Diabetes Foundation (IDF), 
Kaiser Family Foundation (KFF), and the Claremont Colleges Library network to identify 
the sociocultural aspects that negatively affect long-term glycemic control in Black youth.  
Results:​ ​Studies indicate that Black youth with T1D are more likely to face 
disadvantages in ​treatment regimen which are attributed to insurance coverage, 
socioeconomic status, education level, and implicit bias. Most studies demonstrate that these 
factors result in poor glycemic control, which subsequently leads to severe 
dysglycemia-related complications later in life.  
Conclusion and Discussion:​ ​Many Black youth who suffer from T1D receive 
insufficient healthcare, which is often exacerbated by a lack of social and economic 
resources. As a result, they may not have the means to maintain consistent, healthy glycemic 
levels. System-level changes are necessary to change the morbidity and mortality of T1D in 
Black youth. ​Future research should include the analysis of other racial minority groups in 
order to uncover additional institutional disparities. 
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Intro​duction 
In the United States, over 30 million people suffer from diabetes mellitus (DM). Of 
this population, the ​Centers for Disease Control and Prevention​ (CDC) estimates that 5% 
have been diagnosed with type 1 diabetes (T1D) — nearly 200,000 of whom are under 20 
years old. The ​American Diabetes Association​ (ADA) defines T1D as a metabolic disease 
that negatively affects insulin production and prevents ​glycemic control​.  By definition, the 1
body is unable to produce insulin sufficiently, thereby causing elevated levels of glucose in 
the bloodstream. Before official diagnosis, a person suffering from T1D may experience 
symptoms of ​dysglycemia​ ranging from ​polyuria​ and ​polydipsia​ to sudden, rapid weight 
loss. These symptoms and the eventual diagnosis of T1D are more likely to occur during 
adolescence. When comparing racial statistics in the United States, White Americans are 
more likely to​ develop​ T1D than Black Americans (Dabelea ​et al​., 2014). Despite the ​smaller 
proportion ​of Blacks suffering from T1D compared to Whites, Black people are 2.4 times 
more likely to die from severe complications related to the disease (Spanakis and Golden, 
2013). These statistics raise concerns regarding the contribution of external factors that may 
be causing disproportionately negative outcomes. 
 Long-term survivors of T1D are more likely to face severe complications such as 
kidney failure, lower-limb amputations, depression, and even death as a result of prolonged, 
poor glycemic control. However, in an epidemiological review of diabetes and 
diabetes-related complications led by Spanakis ​et al​. (2013), the study revealed that 
outcomes are significantly worse for Black people in terms of cardiovascular health, 
1 All bolded terms are defined in the glossary 
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retinopathy​, ​nephropathy​, ​neuropathy​, and ​end-stage renal disease (ESRD)​. 
Interestingly, this trend also exists for the other racial minority groups, such as Mexican and 
Native Americans, that were included in this study. Given the severity of these 
complications, it is critical to identify and eliminate the genetic, racial, and socioeconomic 
obstacles that characterize this disease. 
Unfortunately, there are few studies that focus specifically on T1D complications in 
Black children and adolescents. In general, there is very limited involvement of Black T1D 
patients in clinical trials, which negatively affects the representative nature of this research. 
In addition, in most of the studies that are currently available, data for Black T1D patients is 
often ​grouped​ with type 2 diabetes incidences. Therefore, this thesis seeks to compile current 
literature regarding how behavioral and socioeconomic disparities affect those who are 
diagnosed during childhood and lead to worse T1D complications over time. Specifically, the 
present study will focus on how​ ​implicit bias and disparities in treatment method, insurance 
coverage, education, and socioeconomic status​ ​correlate with extreme dysglycemia 
complications. ​With this information we can draw conclusions as to how we, as a society, 
can attempt to remedy these disparities. Understanding the source and cause of the increase 
in T1D-related incidences among the Black community will enable legislators, doctors, and 
researchers to develop effective policies that prevent or slow the rising prevalence of this 
disease.  
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Background Information 
Genetic Factors 
In order to understand the varying effects that T1D has on Blacks in comparison to 
other racial groups, it is important to have a thorough understanding of the disease itself. To 
begin, the development of T1D starts at the genetic level. Although family history is often 
considered a major indicator of T1D susceptibility, surprisingly, only 20% of people 
diagnosed with T1D have a known family history of the disease (​CDC, 2018; ​Tao ​et al.​, 
2010​)​. Thus, familial relationships do not necessarily indicate the likelihood of developing 
T1D. Rather, as proven by​ ​genome-wide association study (GWAS) meta-analyses, it is the 
presence of specific genetic markers that determine T1D progression. In a study completed 
by Robertson et.al. (2009), 41 distinct loci were found in the ​Type 1 Diabetes Genetics 
Consortium​ (T1DGC) and associated with T1D risk. While the exact impact of each locus is 
still being examined, research suggests that the presence of islet autoimmunity also ​serves as 
an indicator of T1D susceptibility​. Further, the amount of islet autoantibodies positively 
correlates with the likelihood of disease development. According to Jacobsen​ et al. ​(2018), 
the progression of T1D occurs in three stages determined by the level of beta-cell destruction 
in the pancreas:​ Stage one​ is characterized by the presence of two or more islet 
autoantibodies with ​normoglycemia​, followed by progression to dysglycemia in​ stage two​, 
and the eventual adherence to diabetes criteria set forth by the ADA in​ stage three​.​ ​In short, 
early manifestations of T1D have little to no symptoms until substantial loss of beta-cell 
mass occurs during stage 3. At this point, the pancreas no longer produces a sufficient 
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amount of insulin to maintain glucose homeostasis, resulting in ​diabetic ketoacidosis (DKA) 
(​Robertson and Rich, 2018)​. In summary,​ ​genetic factors such as autoimmune pancreatic 
islets and genetic markers are thought to be involved in each stage of the development of 
T1D at varying levels. The presence of these factors thereby determine the rate of 
progression and subsequent ​occurrence ​of diabetic complications. 
Prevention 
 At this point in time, there are no known methods that can fully prevent the 
development of T1D. Due to the lack of obvious symptoms as defined by stage one, type 1 
diabetics may not recognize disease onset until dysglycemia is severe. Currently, the only 
way to predict and potentially improve later symptoms of DKA is to enact autoantibody 
screening programs (​Jacobsen ​et al​., 2018)​. This method is particularly effective among 
children and adolescents due to their young age.​ ​In support of this solution, Deylami ​et al​. 
(2018) found that public awareness campaigns for earlier screening of T1D leads to earlier 
diagnosis. Thereby, earlier screening decreases levels of DKA at onset relative to those who 
are diagnosed later. Currently, researchers are looking to identify other methods of pre-T1D 
management such as diet, exercise, and glutamic acid decarboxylase (GAD) therapy that can 
be used to prevent the loss of beta-cell function in newly diagnosed patients (Shalitin and 
Chase, 2013). Above all, a better understanding of the causes of islet autoimmunity is needed 
before an official prevention method can be developed. 
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Treatment Options 
After diagnosis, physicians suggest management care in the form intensive insulin 
therapy in the form of daily insulin injections (MDI) or the use of a continuous subcutaneous 
insulin infusion (CSII) (​Boland ​et al​., 2000​). While both products aim to regulate blood 
glucose levels, MDI requires insulin to be injected via syringe multiple times daily, whereas 
CSII provides continuous delivery of short-acting insulin directly into the bloodstream. Both 
methods require the patient to be educated on how to match insulin dosage with food intake, 
blood glucose levels, and anticipated physical activity (​Cummins​ et al​., 2010)​.​ ​In general, 
CSII allows for more flexibility in regards to food intake and physical activity because it 
simulates physiologic insulin response better than MDI. This significantly impacts youth 
with T1D because they are more likely to be active and possess inconsistent eating patterns, 
such as snacking and higher levels of carb intake (Shalitin and Chase, 2013). ​The Diabetes 
Control and Complications Trial (DCCT) of 1987 showed that consistent, intensive insulin 
therapy plays an important role in improving glycemic control and T1D outcomes. To 
accomplish this, the DCCT examined the physiological and psychological responses to CSII 
and MDI in adolescents with T1D. The study spanned 12 months and the results were used to 
determine the most effective treatment regimen for adolescents. Participants using CSII 
exhibited better glycemic control and experienced 50% less dysglycemia incidents than 
participants using MDI. Although self-reports completed by the participants indicated overall 
improvements in self-efficacy and depression with both treatment methods,​ ​patients reported 
that CSII-treatments made it easier to cope with diabetes which improved their overall 
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quality of life (​Boland ​et al., ​2000)​. Thus, while both MDI and CSII have been proven to be 
effective glycemic regulators, CSII includes added personal-ease benefits, especially for 
young people with T1D.  
Regardless of the treatment method,​ both require periodic measurements of blood 
glucose levels. Daily self-monitoring of blood glucose (SMBG)​ ​provides an intermittent 
representation of glucose levels, while the use of a Continuous Glucose Monitor (CGM) 
illustrates glucose variability over a 24 hour period (Shalitin ​et al​., 2012). Accurate and 
consistent measurements of blood glucose ensure that the current treatment method is 
working, which helps prevent instances of dysglycemia. ​As demonstrated, long-term diabetes 
complications can be prevented with close monitoring and well-managed glycemic control. 
Cost 
Considering patients with T1D typically suffer from the disease for a longer period of 
time due to earlier diagnoses, treatment represents a significant lifelong cost and time 
commitment (​Jacobsen ​et al​., 2018)​. As required, regulating T1D requires daily insulin and 
constant monitoring for survival. Since 2002, the average price of insulin has increased 
steadily from roughly $40 a vial to $130.​ ​Although the amount of insulin needed varies per 
person, one vial typically lasts 1.5 weeks before the prescription must be refilled (​Hua, ​et al.​, 
2016)​. ​ ​In total, average yearly medical expenditures for families with children diagnosed 
with T1D is approximately $12,000 for children aged 3 to 18 (​Tao ​et al​., 2010)​. The same 
study also found that young patients with T1D who stay at least one night in the hospital 
spend an average total of $23,137 per year. It is important to note, however, that in the 
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United States, the shared medical costs for each family depends on their insurance 
coverage— a topic that will be discussed later. Nevertheless, studies have shown that the 
T1D has a substantial economic impact, making socioeconomic status a crucial component of 
understanding the full extent of the disease (​Tao ​et al​., 2010)​. 
Given the background information presented on T1D prevention, diagnosis, and 
management care, ​next I will use previous literature to examine the effects of external factors 
such as socioeconomic status, insurance status, implicit bias, and education levels on T1D 
outcomes in Black youth.  
  
10 
 
 
RACIAL DISPARITIES IN THE DIAGNOSIS AND TREATMENT OF TYPE 1 DIABETES IN BLACK AMERICAN YOUTH 
 
 
 
Literature Review 
Given the multidisciplinary nature of this topic, a relevant literature review spans the 
fields of economics, public health, social psychology, and public policy. The majority of 
health-related studies regarding T1D do not differentiate between race or age, which neglects 
the underlying differences that exist. Therefore, more research is needed in the realm of how 
demographic factors, especially those of White and Black people, may impact health 
outcomes.  
Proposed contributors to the disparities faced by Black youth 
I. Treatment method 
Amongst epidemiological findings, Paull ​et al​. (2015) observed a large population of 
childhood type 1 diabetics in order to examine how their treatment regimen affected 
glycemic control​. In this study, diabetes management and clinical outcomes were compared 
among 8841 White and 697 Black participants under 18 years old who had been diagnosed 
with T1D for over a year. Results showed that CSII-treatment was significantly higher in 
White participants than in Black participants across all levels of socioeconomic and 
insurance status. In addition, Black participants experienced poorer glycemic control than 
White participants, which resulted in more DKA/hyperglycemia and severe hypoglycemic 
events. Given the​ ​added benefits of CSII-treatment in terms of glycemic control, ease, and 
personal satisfaction as discussed by the DCCT study group, this leads us to question why 
more children are not using insulin-pump therapy. Of course it is important to acknowledge 
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that pump treatment is a large investment, however, the wide range of participants of various 
income levels in this study indicates that disparities in treatment method transcend 
socioeconomic class. Unfortunately, Paull ​et al​. fails to mention how each participant chose 
their treatment regimen ​(i.e. financial factors, experience and comfort level) ​making the 
source of this disparity unclear. Certainly, circumstances can only be determined on a 
case-by-case basis. Regardless, whether the discrepancy exists due to cost or lack of 
information, given the results of this study, it is clear that marked disparities in insulin 
therapy methods and outcomes exist between Black and White people. As demonstrated, 
barriers to CSII-treatment and optimal glycemic control exist beyond socioeconomic status 
and should be explored across all ethnic groups. 
II. Insurance coverage and socioeconomic status 
Access to health care includes the access to medical professionals and facilities as 
well as the ability to receive services and afford the associated fees.​ ​Regulating T1D has an 
annual cost of $14.4 billion in the United States in terms of medical expenditures and lost 
income ​(​Tao ​et al​., 2010). Individual costs for patients and their families may vary depending 
on many factors including, but not limited to, insurance coverage and treatment plan. In the 
United States, there are severe gaps in health coverage among the Black population— 
especially among children. Statistically, 6% of Black children are uninsured, 41% are insured 
through private coverage, and 54% receive Medicaid or other public assistance. In 
comparison, 4% of White children are uninsured, 66% receive private coverage, and 30% 
receive Medicaid or other public assistance (KFF, 2018). While the rate of uninsured Black 
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children has greatly decreased since the enactment of the Affordable Care Act, Blacks are 
still more likely than Whites ​and other higher socioeconomic status groups ​to be uninsured 
(​Cohen, ​et al​. 2016)​. 
For many, particularly those of middle-class status, health insurance stands as an 
institutional barrier to preventive healthcare access regardless of race. In a recent study 
conducted at Yale University, ​Herkert ​et al​. (2018) suspects that healthcare is unaffordable 
for middle-class patients with an income between $25,000 and $100,000 due to the fact that 
they are simultaneously ineligible for Medicaid, unable to afford private health insurance, 
and cannot afford unsubsidized costs.​ ​Further, the study shows that T1D patients within this 
income range are more likely to reduce necessary insulin usage, despite necessity, as a way 
to save money. Consequently, these patients are prone to poor glycemic control. As expected, 
supporting ​research suggests that the uninsured have overall worse health outcomes than the 
insured (Institute of Medicine, 2009). Many communities have attempted to remedy 
healthcare inaccessibility with the installment of free clinics and community health centers, 
however, in reality, many of these facilities lack specialty services. In terms of T1D, 
specialty services may be necessary to address serious optical, endocrine, and dermatology 
issues that may arise as a consequence of poor glycemic control (​American Diabetes 
Association, 2012)​. Thus, those without insurance are more likely to suffer from these 
complications.  
Considering the uninsured population constitutes a relatively small percentage of 
Black children, it is also important to critically view the outcomes of those with health 
insurance— particularly through government-assistance programs. Unfortunately, studies 
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have shown that disparities exist among those using public assistance such as Medicaid in 
comparison to those with private insurance, further proving the inaccessibility of healthcare. 
According to the RAND study of 1984 which was conducted by the U.S. Department of 
Health and Human Services, government-run health insurance plans do not ensure better care 
nor a better quality of life despite subsidized costs, which suggests that disparities exist 
outside of health insurance. Across the country, there are a limited number of health facilities 
that accept Medicaid, which may make it difficult for people to find physicians and 
specialists depending on their geographic location. Moreover, facility limitations lead to 
overcrowded emergency rooms and clinics, which results in longer wait times for all patients 
before they can be treated. For many lower-middle class families with less flexible work 
obligations, the time commitment associated with a doctor’s visit may deter them from 
seeking regular medical treatment. The work culture in the U.S. does not easily allow for 
low-income individuals to take time off of work to schedule and attend doctors appointments. 
Considering most children cannot be treated without an adult present at their appointments, it 
may be difficult for them to receive regular medical care and/or specialized help until 
dysglycemia complications are severe. In many cases, parents taking time off of work may 
also result in their inability to afford life-saving medication such as insulin, for their children. 
In relating T1D in children to socioeconomic status, there are significant relationships 
between race, low-income, and poor glycemic control. In short, households that do not have 
disposable income for treatment often​ ​underutilize effective services pertaining to 
preventative health services and early detection, which may cause otherwise easily-solved 
complications to worsen drastically over time (Adepoju, 2015). In a study conducted by 
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researchers at the Journal of the American Medical Association in 1992, physicians were 
interviewed regarding the occurrences of avoidable hospitalizations they have encountered 
with Medicaid or uninsured patients in comparison to those with private insurance. Together, 
the physicians revealed that there is an overall higher rate of hospitalization for conditions 
that would have benefitted from preventative or aggressive treatments. Again, this study 
suggests that Medicaid recipients do not have access to higher quality care, despite having 
health insurance. In short, insurance coverage does not necessarily correlate to better health. 
The precise impact of socioeconomic status on Black youth with T1D is difficult to 
establish due to the limited participation of high-income Black families in epidemiological 
studies. Therefore it is difficult to disentangle the effects of race and income on healthcare 
access and treatment options. 
III. Education 
Education level is not only a major indicator of socioeconomic status but in terms of 
medical care, it encompasses the ability to process information, engage with medical 
professionals, and make informed decisions on how to handle diagnoses. In addition, higher 
education levels often lead to a better understanding of the importance of exercise and a 
healthy diet, both of which aid in glycemic control in type 1 diabetics. In the U.S., 14% of 
Blacks have less than a high school diploma (​KFF, 2018)​. For children of parents with low 
education levels, they are often at a disadvantage due to the fact that their parents may be 
unable to understand clinical terms in the doctor’s office. Because family support can 
translate to better quality of care, it is important that a child has a trusted adult who 
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understands the severity of their diagnosis and is able to teach them how to regulate their 
own glucose levels.  
IV. Implicit bias among medical professionals 
To ensure accessibility for all patients, medical professionals are responsible for 
fostering an objective and impartial environment. In general, a patient’s comfort level with 
their physician affects their willingness to ask important questions and seek help, which 
thereby affects their ability to manage their disease. Unfortunately, a ​considerable amount of 
evidence suggests that a patient’s sociodemographic characteristics have an impact on their 
interactions with physicians— regardless of intentionality​ ​(Van Ryn and Burke, 2000; 
Johnson ​et al.​, 2017)​. This concept is best defined by ​implicit bias​; a psychological concept 
that describes the unconscious attribution of stereotypes to a particular social group. 
Unconscious discrimination among health professionals raises concerns about how a 
physician’s judgment of their patients influences the diagnosis, treatment recommendations, 
and quality of care they provide. In a study completed by Van Ryn and Burke (2000), survey 
data was used to examine the degree to which a patient’s race and socioeconomic status 
affects a physicians' perception of their patient. Results of the study indicate that​ ​physicians 
tend to perceive Blacks, especially those of lower and middle class, more negatively than 
Whites in terms of the risk of noncompliance to medical advice, intelligence, and personality. 
In a similar study, Johnson ​et al.​ (2017) measured implicit racial bias of resident physicians 
using the Adult and Child Race Implicit Association Tests (IATs). They found that the 
residents exhibited moderate pro-White and anti-Black bias towards both adults and children. 
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Of note, resident demographic and specialty characteristics were not controlled, which 
suggests that pediatric residents are just as susceptible to implicit bias as physicians in other 
fields. In terms of T1D, implicit bias may impact the extent to which a physician explains a 
diagnosis to their patient as well as the treatment regimens that are suggested. In the event 
that the explanations are insufficient, patients are undoubtedly more prone to experience poor 
glycemic control and develop complications over time.  
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Conclusion, Discussion & Future Research 
The aim of this thesis is to address the increase in T1D diagnoses and how 
insufficient social and economic resources negatively affects the morbidity and mortality of 
Black youth with this disease.​ ​Research suggests that external factors such as wealth, 
insurance status, education level, and implicit bias from medical professionals affects a 
patient’s ability to maintain consistent, healthy glycemic levels. As discussed, prolonged, 
poor glycemic control leads to severe complications over time. Although some may argue 
that it is the parent’s responsibility to care for and manage the overall health of their child, 
studies show that the disparities in the diagnosis and management of T1D transcend 
circumstances beyond parental control. Thus, I propose that system-level changes are 
necessary to reduce the morbidity and mortality of T1D in Black youth.  
With regards to disparities in treatment method, it is critical that patients of all 
backgrounds feel comfortable in medical spaces. Thus, physicians should be required to 
periodically take courses and assessments on implicit bias over the course of their career. 
Being in a position of power, it is a physician’s responsibility to be equipped with 
psychological tools to address their own unconscious bias and uphold their hippocratic oath. 
This will ensure that each patient receives adequate information about their diagnosis and 
treatment options regardless of race, socioeconomic status, or education level. In addition, 
according to the implicit bias studies completed by ​Johnson ​et al.​ (2017)​, Black doctors 
showed less bias towards their patients overall. Thus, increasing the representation of Black 
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medical professionals is expected to have a positive impact on physician-patient interactions 
and the outcomes of Black patients.  
Due to the limitations of epidemiological ​studies that focus specifically on T1D 
complications in Black youth, f​uture research should include Black patients of diverse 
socioeconomic and educational backgrounds as well as analysis of the issues faced by 
members of other racial and ethnic minority groups. In doing so, connections between 
institutional factors that contribute to health disparities can be better evaluated. Such studies 
should push policymakers to address and reduce these inequities. 
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Glossary   2
Diabetic ketoacidosis an abnormal condition of reduced alkalinity of the blood and 
tissues that is marked by sickly sweet breath, headache, nausea 
and vomiting, and visual disturbances that is a result of 
excessive acid production resulting from increased levels of 
ketones in the blood 
Dysglycemia the presence of a normal concentration of glucose in the blood 
End-stage renal disease 
(ESRD) 
the final stage of kidney failure (as that resulting from diabetes, 
chronic hypertension, or glomerulonephritis) that is marked by 
the complete or nearly complete irreversible loss of renal 
function 
Glycemic control control of ​the presence of glucose in the blood 
Nephropathy an abnormal state of the kidney 
Neuropathy damage, disease, or dysfunction of one or more nerves 
especially of the peripheral nervous system that is typically 
marked by burning or shooting pain, numbness, tingling, or 
muscle weakness or atrophy, is often degenerative, and is 
usually caused by injury, infection, disease, drugs, toxins, or 
vitamin deficiency 
Normoglycemia the presence of a normal concentration of glucose in the blood 
Polydipsia excessive or abnormal thirst 
Polyuria excessive secretion of urine 
Retinopathy any of various noninflammatory disorders of the retina 
including some that cause blindness 
2 All definitions were sourced from the Merriam-Webster Medical Dictionary 
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